GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) » Definitions » Equity-to-Asset

GlaxoSmithKline Pharmaceuticals (BOM:500660) Equity-to-Asset : 0.50 (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GlaxoSmithKline Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹17,776 Mil. GlaxoSmithKline Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was ₹35,566 Mil. Therefore, GlaxoSmithKline Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.50.

The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

BOM:500660' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48   Med: 0.56   Max: 0.76
Current: 0.5

During the past 13 years, the highest Equity to Asset Ratio of GlaxoSmithKline Pharmaceuticals was 0.76. The lowest was 0.48. And the median was 0.56.

BOM:500660's Equity-to-Asset is ranked worse than
59.06% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs BOM:500660: 0.50

GlaxoSmithKline Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Equity-to-Asset Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.48 0.58 0.52 0.50

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 - 0.47 - 0.50

Competitive Comparison of GlaxoSmithKline Pharmaceuticals's Equity-to-Asset

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Equity-to-Asset falls into.



GlaxoSmithKline Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

GlaxoSmithKline Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=17776.397/35566.175
=0.50

GlaxoSmithKline Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=17776.397/35566.175
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pharmaceuticals  (BOM:500660) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


GlaxoSmithKline Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pharmaceuticals (BOM:500660) Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400 030
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives most of its revenue from India.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Headlines

No Headlines